LEONID VOLFINZON: Open Payments
NPI 1952403933 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$617 in 26 payments from 12 companies in 2025. Trend: 2023 $214 · 2024 $404 · 2025 $617
Food & beverage: $617
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $198 |
| Ardelyx, Inc. | 2 | $66 |
| Amgen Inc. | 3 | $63 |
| AstraZeneca Pharmaceuticals LP | 2 | $59 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $49 |
| Merck Sharp & Dohme LLC | 2 | $48 |
| Novo Nordisk Inc | 1 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $22 |
Products named: UBRELVY, IBSRELA, FARXIGA, LINZESS, JARDIANCE, LAGEVRIO, QULIPTA, OTEZLA.
Industry payments across NY — which companies pay providers there.
